TheranosticTrials.org

Clinical Trial · NCT06288113

Re-Treatment With 177Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer: A Prospective Phase 2 Trial (RE-LuPSMA STUDY)

Overview

This phase II trial tests how well re-treatment with 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic), that continues to grow or spread after the surgical removal of the testes or medical treatment to block androgen production (castration-resistant), and that has shown a favorable response to initial treatment with 177Lu-PSMA-617. 177Lu-PSMA-617 is a radioactive drug. It binds to a protein called prostate specific membrane antigen (PSMA), which is expressed by some types of prostate tumor cells. When 177Lu-PSMA-617 binds to PSMA-expressing tumor cells, it delivers radiation to the cells, which may kill them. Re-treatment with 177Lu-PSMA-617 in patients who had a favorable response to initial 177Lu-PSMA-617 treatment may improve survival outcomes and disease response in patients with metastatic castration-resistant prostate cancer.

Sponsor

Jonsson Comprehensive Cancer Center (UCLA)

Phase

Phase 2

Contacts

Maria Contreras (Clinical Research Coordinator)

mmcontreras@mednet.ucla.edu

310-825-7336

Hamzah Alam (Clinical Research Coordinator)

halam@mednet.ucla.edu

310-206-7372

ClinicalTrials.gov

NCT06288113

Drug / Compound

PSMA-617

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: DOTA
Linker: Glutamate-urea-Lysine

Eligibility

Inclusion

  • Patients must have received at least one regimen of chemotherapy for mCRPC
  • Patients must have previously completed at least 4 cycles of 177Lu-PSMA-617 therapy
  • Patients must have received at least one androgen receptor signaling inhibitor (ARSI)
  • Patients must have mCRPC

Exclusion

  • Patient received new prostate cancer therapy within two months of completing the first regimen of 177Lu-PSMA-617 therapy
  • Patient received myelosuppressive therapy or other radionuclide therapy within the last 6 weeks
  • Patient with creatinine clearance < 50 mL/min

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…